Anavex Life Sciences (AVXL) Stock Forecast, Price Target & Predictions
AVXL Stock Forecast
Anavex Life Sciences stock forecast is as follows: an average price target of $11.00 (represents a 50.68% upside from AVXL’s last price of $7.30) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
AVXL Price Target
AVXL Analyst Ratings
Anavex Life Sciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 06, 2022 | - | Cantor Fitzgerald | $11.00 | $8.54 | 28.85% | 50.68% |
Anavex Life Sciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $7.30 | $7.30 | $7.30 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jul 22, 2024 | EF Hutton | - | Buy | Initialise |
Jan 03, 2023 | Barclays | Equal-Weight | Equal-Weight | Hold |
Jan 03, 2023 | Keefe, Bruyette & Woods | Outperform | Outperform | Hold |
Jan 03, 2023 | Needham | Buy | Buy | Hold |
Jan 03, 2023 | Piper Sandler | Overweight | Overweight | Hold |
Dec 06, 2022 | Cantor Fitzgerald | - | Neutral | Downgrade |
Anavex Life Sciences Financial Forecast
Anavex Life Sciences Revenue Forecast
Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Avg Forecast | $111.56M | $71.73M | $45.53M | $45.92M | - | - |
High Forecast | $111.56M | $71.73M | $45.53M | $45.92M | - | - |
Low Forecast | $111.56M | $71.73M | $45.53M | $45.92M | - | - |
# Analysts | 1 | 1 | 1 | 1 | - | - |
Surprise % | - | - | - | - | - | - |
Anavex Life Sciences EBITDA Forecast
Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - |
EBITDA | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - |
Anavex Life Sciences Net Income Forecast
Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - |
Net Income | - | - | - | - | - | - |
Avg Forecast | $-15.22M | $-19.44M | $-16.91M | $-16.06M | $-13.81M | $-13.53M |
High Forecast | $-15.22M | $-19.44M | $-16.91M | $-16.06M | $-13.81M | $-13.53M |
Low Forecast | $-15.22M | $-19.44M | $-16.91M | $-16.06M | $-13.81M | $-13.53M |
Surprise % | - | - | - | - | - | - |
Anavex Life Sciences SG&A Forecast
Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - |
SG&A | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - |
Anavex Life Sciences EPS Forecast
Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | - | - |
EPS | - | - | - | - | - | - |
Avg Forecast | $-0.18 | $-0.23 | $-0.20 | $-0.19 | $-0.16 | $-0.16 |
High Forecast | $-0.18 | $-0.23 | $-0.20 | $-0.19 | $-0.16 | $-0.16 |
Low Forecast | $-0.18 | $-0.23 | $-0.20 | $-0.19 | $-0.16 | $-0.16 |
Surprise % | - | - | - | - | - | - |
Anavex Life Sciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BTAI | BioXcel Therapeutics | $0.64 | $12.00 | 1775.00% | Buy |
KOD | Kodiak Sciences | $3.90 | $31.60 | 710.26% | Buy |
NVAX | Novavax | $9.12 | $58.00 | 535.96% | Buy |
INMB | INmune Bio | $6.25 | $22.00 | 252.00% | Buy |
ANVS | Annovis Bio | $8.73 | $25.67 | 194.04% | Buy |
IOVA | Iovance Biotherapeutics | $11.44 | $21.00 | 83.57% | Buy |
VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
AVXL | Anavex Life Sciences | $7.30 | $11.00 | 50.68% | Buy |
AXSM | Axsome Therapeutics | $87.25 | $117.83 | 35.05% | Buy |
TGTX | TG Therapeutics | $24.36 | $26.40 | 8.37% | Buy |
MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
EXEL | Exelixis | $34.29 | $30.50 | -11.05% | Buy |
AVXL Forecast FAQ
Is Anavex Life Sciences a good buy?
Yes, according to 7 Wall Street analysts, Anavex Life Sciences (AVXL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of AVXL's total ratings.
What is AVXL's price target?
Anavex Life Sciences (AVXL) average price target is $11 with a range of $11 to $11, implying a 50.68% from its last price of $7.3. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Anavex Life Sciences stock go up soon?
According to Wall Street analysts' prediction for AVXL stock, the company can go up by 50.68% (from the last price of $7.3 to the average price target of $11), up by 50.68% based on the highest stock price target, and up by 50.68% based on the lowest stock price target.
Can Anavex Life Sciences stock reach $11?
AVXL's average twelve months analyst stock price target of $11 does not support the claim that Anavex Life Sciences can reach $11 in the near future.
What are Anavex Life Sciences's analysts' financial forecasts?
Anavex Life Sciences's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-27.333M (high $-27.333M, low $-27.333M), average SG&A $0 (high $0, low $0), and average EPS is $-0.323 (high $-0.323, low $-0.323). AVXL's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $274.74M (high $274.74M, low $274.74M), average EBITDA is $0 (high $0, low $0), average net income is $-67.628M (high $-67.628M, low $-67.628M), average SG&A $0 (high $0, low $0), and average EPS is $-0.8 (high $-0.8, low $-0.8).